natriuretic peptide

Mouse Brain Natriuretic Peptide-45 (BNP-45, mouse) is a circulating variant of the mouse brain natriuretic peptide derived from the mouse heart. It exhibits powerful hypotensive and natriuretic properties.

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is an isoform of the rat brain natriuretic peptide extracted from the rat heart, exhibiting significant hypotensive and natriuretic effects [1].

BNP-45 (rat) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Imelciment (REGN-9035) is a humanised monoclonal antibody targeting NPR1, which can be used for research into heart failure.

AP 811, a selective antagonist of the atrial natriuretic peptide clearance receptor (APN-CR, NPR3) with a K i value of 0.48 nM, exhibits remarkable selectivity for NPR3 over NPR1 by more than 20,000-fold. Moreover, AP 811 effectively eliminates ANP-induced pump stimulation.

Urodilatin, an analogue of ANF-(99-126), serves as a diuretic-natriuretic regulatory peptide with applications in the study of acute renal failure, congestive heart failure, and bronchial asthma, among other conditions [1].

Atriopeptin III (rat) (ANP 127-150), a 24-amino acid atrial peptide, functions as a powerful vasodilator and natriuretic/diuretic agent, enhancing renal functions and reducing blood pressure in a rat model with ureter-obstructed kidneys. It is utilized in research concerning chronic renal failure [1].

Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. It is an agonist of natriuretic peptide receptors (NPRs), with Kd values of 7.3 and 13 pM for NPR-A and NPR

Nesiritide, a 32-amino acid natriuretic peptide and recombinant form of human brain natriuretic peptide, enhances vasorelaxation ex vivo in porcine hearts from an acute coronary occlusion model when given as a 2 µg/kg bolus dose followed by a 0.01 µg/kg per minute infusion, facilitated by the calcium ionophore A23187. Formulations containing nesiritide have been utilized in managing congestive heart failure.

NPRA agonist-11 (Example 161) is an NPRA (NPR1) agonist with AC50 values of 1.681 μM and 0.989 μM for human and monkey, respectively. It is applicable in research on cardiovascular and other diseases.

A 71915, an atrial natricuretic factor receptor antagonist, blocks physiological effects of angiotensin.

Ethiazide is a thiazole diuretic that inhibits renal tubular reabsorption of sodium and water, leading to increased urine output, reduced fluid retention, and decreased blood volume and blood pressure, Ethiazide is commonly applied in cardiovascular and renal research to study diuretic mechanisms and hypertension management.

Vixticibart is a humanized IgG4κ antibody targeting NPR1, with HumanIgG4(S228P) kappa serving as its corresponding isotype control.

REGN-7544 is a humanised monoclonal antibody targeting NPR1, which blocks and inhibits NPR1 to increase blood pressure, and can be used for research into hypotension, septic shock, and postural tachycardia syndrome.

Baloncibart is a human IgG4K monoclonal antibody that targets NPR1.

Ularitide is a 32-amino acid peptide derived from (95-126 residues) of ANP PROHORMONE (1-126 residues). It isn't biologically inactivated by a peptidase from dog kidney cortex membranes.

C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.

Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32-amino acid polypeptide hormone synthesized by ventricular cardiomyocytes in response to myocardial cell stretching (cardiomyocyte distension)[1].

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) with endocrine effects on fluid homeostasis and blood pressure, holding promise for cardiovascular disease research.

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP that functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis induced by histamine, 5-HT, or Forskolin, while exhibiting strong endothelial-derived relaxation properties and acting as a growth inhibitor.

Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)), a peptide hormone produced by the atrial myocardium, critically regulates blood pressure, fluid balance, and electrolyte homeostasis [1] [2].

Dendroaspis Natriuretic Peptide, a vasodilator peptide, is derived from animal venom [1].

Brain natriuretic peptide-32 (BNP-32), a fragment of the proBNP cardiovascular hormone precursor, exhibits affinity for natriuretic peptide receptors in rat vascular smooth muscle cells (IC50 = 7.3 nM) and promotes cGMP accumulation within these cells (EC50 = 170 nM). Additionally, BNP-32 effectively mediates the relaxation of norepinephrine-precontracted isolated rat aortic strips (EC50 = 6.7 nM). Upon administration at a dosage of 3 µg/kg, it elevates urine and urinary electrolyte outputs and induces hypotension in rats.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.